881 results on '"Zaanan A"'
Search Results
2. Peritoneal Tumour DNA in Peritoneal Fluid: Emerging Tool for Peritoneal Metastasis Detection
3. Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
4. Is laparoscopic approach as treatment of large gastric GIST acceptable?
5. Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations
6. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
7. Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations
8. A systematic review of minimal length of lroximal margin in gastric adenocarcinoma resection
9. Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
10. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study
11. Biomarkers for Immunotherapy in Gastrointestinal Cancers
12. Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study
13. New developments and standard of care in the management of advanced gastric cancer
14. Treatment of gastric adenocarcinoma: A rapidly evolving landscape
15. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives
16. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency
17. Pembrolizumab en association à la chimiothérapie de première ligne du traitement des adénocarcinomes gastriques ou de la jonction œsogastrique, HER2 négatifs, localement avancés non résécables ou métastatiques
18. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
19. Immunothérapie dans le traitement du cancer gastrique métastatique
20. Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort
21. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
22. Detection of Microsatellite Instability in Colorectal Cancer Tissue and Plasma samples using a new Multiplex Droplet Digital PCR kit
23. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study
24. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
25. Systemic treatments with tyrosine kinase inhibitor and platinum-based chemotherapy in patients with unresectable or metastatic hepatocholangiocarcinoma
26. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
27. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study
28. Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire : l’essai de phase II GERCOR NEONIPIGA vient d’être ouvert au recrutement
29. New developments and standard of care in the management of advanced gastric cancer
30. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
31. High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer
32. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
33. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
34. Biomarkers for Immunotherapy in Gastrointestinal Cancers
35. Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study
36. Valeur prédictive et pronostique du phénotype MSI dans le cancer du colon non métastatique : qui et comment traiter ?
37. Immunotherapy in advanced gastric cancer, is it the future?
38. Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays
39. Adjuvant chemotherapy benefit according to T/N stage in small bowel adenocarcinoma: a large retrospective multicenter study
40. Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort studyResearch in context
41. Tislelizumab en deuxième ligne de traitement du carcinome épidermoïde avancé de l’œsophage après échec des sels de platine
42. A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen
43. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
44. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
45. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer
46. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)
47. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers
48. Exploring the best treatment options for BRAF-mutant metastatic colon cancer
49. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
50. Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.